A practical reference on tirzepatide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-14. Anything still debated is marked as such rather than presented as settled.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
==== 30th anniversary celebrations ==== Berlin planned a week-long arts festival from 4 to 10 November 2019 and a citywide music festival on 9 November to celebrate the 30th anniversary. On 4 November, outdoor exhibits opened at Alexanderplatz, the Brandenburg Gate, the East Side Gallery, Gethsemane Church, Kurfürstendamm, Schlossplatz, and the former Stasi headquarters in Lichtenberg.
Militarily, the Combine make use of both synthetics, creatures augmented with machinery, and traditional machines such as armored personnel carriers and attack helicopters. The most prominent of the synthetic machines are the insect-like gunships; and Striders, 50-foot-tall (15 m) armored creatures which walk on three legs and are armed with a high powered cannon and a head-mounted pulse turret. In Episode Two, the Hunter, a smaller equivalent to the Strider, is introduced. These tripodal assault machines fire explosive flechettes at targets and are small enough to maneuver indoors. Other synths are seen near the end of the Half-Life 2, though their roles are not elaborated on. Sentry turrets are also used by the Combine. The Combine often uses headcrabs as a method of bioterrorism against dissidents and refugees, firing artillery shells loaded with the creatures into areas and allowing them to infest said area.
=== Earliest work === The study of hydrogen stable isotopes began with the discovery of deuterium by chemist Harold Urey. Even though the neutron was not realized until 1932, Urey began searching for "heavy hydrogen" in 1931. Urey and his colleague George Murphy calculated the redshift of heavy hydrogen from the Balmer series and observed very faint lines on a spectrographic study. To intensify the spectroscopic lines for publishable data, Murphy and Urey paired with Ferdinand Brickwedde and distilled a more concentrated pool of heavy hydrogen, now called deuterium. This work on hydrogen isotopes won Urey the 1934 Nobel Prize in Chemistry.
Sources: en.wikipedia.org
The effects of PKA results from its ability to phosphorylate serine and threonine residues on many cellular proteins, especially transcription factor cAMP response element binding protein (CREB). cAMP/PKA/CREB axis mediates the inhibition of TNF-alpha release. The killing of phagocytosed bacteria by AMs is dependent upon several distinct microbicidal mechanisms, like the reduced NADPH oxidase-mediated release of ROI. ROI generation by NADPH oxidase is an important bactericidal mechanism after FcR-mediated phagocytosis. PGE2 activates both Gs-coupled EP2 and EP4 receptors by ligation, stimulating cAMP production and subsequent activation of downstream cAMP effectors, PKA and Epac-1; both which in turn impair the phosphorylation and phagosomal membrane translocation of NADPH oxidase component, p47phox, thereby inhibiting the respiratory burst.
==== Field ionization ==== In field ionization, electrons are removed from a species by quantum mechanical tunneling in a high electric field, which results in the formation of molecular ions (M + ̇ in positive ion mode). This ionization method usually takes places in nonpolar or slightly polar organic compounds.
September 13 Trump dismisses concerns over the rapid pace of AI research, following days of warnings from experts in the field about possible existential risks. In a meeting with US officials, the Houthis promise not to attack American or any other commercial vessels, with the exception of those belonging to Saudi Arabia. September 14 The yield on benchmark 10-year U.S. Treasury notes rises above 5% for the first time since October 2023, amid a global bond sell-off as surging oil prices and disruption to Middle Eastern energy supplies fuel renewed fears of inflation. The yield reaches 5.01%, while Brent crude rises above $108 a barrel. U.S. Senator Mitch McConnell returns to the Senate floor following a three-month absence. Trump announces that he is willing to engage with Iran to negotiate a deal. Donald Trump Jr.'s wedding celebration is reported to have been partly funded by a Russian oligarch with close connections to President Vladimir Putin. A court in Boston blocks Trump restrictions on how long foreign students and journalists can remain in the country. The Supreme Court rejects the Trump administration's request to lift an injunction blocking new United States Postal Service restrictions on mail-in voting ahead of the midterm elections. The US Space Force announces that the country now has weapons deployed in orbit, suggesting that the unspecified platforms are needed to compete with adversaries China and Russia.
Radioactive waste is a type of hazardous waste that contains radioactive material. It is a result of various activities, including nuclear medicine, nuclear research, nuclear power generation, nuclear decommissioning, rare-earth mining, and nuclear weapons reprocessing. The storage and disposal of radioactive waste is regulated by government agencies in order to protect human health and the environment. Radioactive waste is broadly classified into three categories: low-level waste (LLW), such as paper, rags, tools, and clothing, which contain small amounts of mostly short-lived radioactivity; intermediate-level waste (ILW), which contains higher amounts of radioactivity and requires some shielding; and high-level waste (HLW), which is highly radioactive and hot due to decay heat, thus requiring cooling and shielding. Spent nuclear fuel can be processed in nuclear reprocessing plants. One third of the total amount has already been reprocessed. With nuclear reprocessing, 96% of the spent fuel can be recycled back into uranium-based and mixed-oxide (MOX) fuels. The residual 4% is minor actinides and fission products, the latter of which are a mixture of stable and quickly decaying (most likely already having decayed in the spent fuel pool) elements, medium lived fission products such as strontium-90 and caesium-137 and finally seven long-lived fission products with half-lives in the hundreds of thousands to millions of years. The minor actinides, meanwhile, are heavy elements other than uranium and plutonium which are created by neutron capture.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.